Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hansoh Pharmaceutical Group Co EV-to-EBIT?
Hansoh Pharmaceutical Group CoHNSPF 86 EV-to-EBIT is 23.93 as of Aug. 11, 2026, which is 2% above its 10-year median of 23.50. GuruFocus rates HNSPF with a GF Score™ of 86/100 and a GF Value™ of $3.15 (Modestly Overvalued). Among 683 Drug Manufacturers companies, Hansoh Pharmaceutical Group Co ranks worse than 66.03% on this metric.
Hansoh Pharmaceutical Group Co (OTCPK:HNSPF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hansoh Pharmaceutical Group Co's Enterprise Value for the quarter that ended in Dec. 2025 was $25,652 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $920 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co EV-to-EBIT Related Terms
Hansoh Pharmaceutical Group Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansoh Pharmaceutical Group Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hansoh Pharmaceutical Group Co's EV-to-EBIT falls into.
Hansoh Pharmaceutical Group Co's current Enterprise Value is $22,028 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $920 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansoh Pharmaceutical Group Co (HNSPF) has a EV-to-EBIT of 23.93 as of Aug. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hansoh Pharmaceutical Group Co and its competitors. This is near median its historical median of 23.50. Over the past decade, Hansoh Pharmaceutical Group Co's EV-to-EBIT has ranged from 10.98 to 68.31. According to the industry distribution chart, Hansoh Pharmaceutical Group Co ranks #451 out of 683 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is Hansoh Pharmaceutical Group Co's EV-to-EBIT too high?
Hansoh Pharmaceutical Group Co's current EV-to-EBIT of 23.93 is near median its 10-year median of 23.50. Over the past 10 years, this metric has ranged from a low of 10.98 to a high of 68.31. The Drug Manufacturers industry median EV-to-EBIT is 15.76. Hansoh Pharmaceutical Group Co's value of 23.93 is 51.8% above this industry median. Based on the distribution chart, Hansoh Pharmaceutical Group Co ranks #451 out of 683 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hansoh Pharmaceutical Group Co ranks #451 out of 683 companies for EV-to-EBIT. This places Hansoh Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-EBIT is 15.76. Hansoh Pharmaceutical Group Co's value of 23.93 is 51.8% above this benchmark. Historically, Hansoh Pharmaceutical Group Co's own EV-to-EBIT has ranged from 10.98 to 68.31 over the past decade. While the company's 10-year median is 23.50 vs. the industry median of 15.76, Hansoh Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.76, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hansoh Pharmaceutical Group Co's current EV-to-EBIT of 23.93 is 51.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hansoh Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hansoh Pharmaceutical Group Co's current EV-to-EBIT is 23.93, which is near median its own 10-year median of 23.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HNSPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.15, compared to a current price of $4.11 — trading 30.5% above its estimated fair value. The current EV-to-EBIT is 23.93, which is near median its 10-year median of 23.50 and 51.8% above the Drug Manufacturers industry median of 15.76. Hansoh Pharmaceutical Group Co's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HNSPF), the current EV-to-EBIT is 23.93 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansoh Pharmaceutical Group Co (HNSPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of $4.11 is trading 30.5% above its estimated GF Value™ of $3.15.
GuruFocus considers Hansoh Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for HNSPF:
EV-to-EBIT: 23.93 (near median its 10-year median of 23.50)
GF Value™: $3.15 vs. price of $4.11 (30.5% above fair value)
Industry Position: 51.8% above the Drug Manufacturers median (#451 of 683)
No single metric tells the full story. See the HNSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
86GF Score
Get the complete analysis for HNSPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HNSPF has been successfully added to your 
